Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety

Nephrology Dialysis Transplantation

Volumn 19, Issue 6, 2004, Pages 1576-1580

  Michael, Beckie ^a   Coyne, Daniel W ^b   Folkert, Vaughn W ^c   Dahl, Naomi V ^d   Warnock, David G ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Watson Laboratories Inc   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Haemodialysis; Intravenous iron; Iron deficiency; Iron dextran sensitivity; Sodium ferric gluconate complex

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; FERRIC GLUCONATE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANAPHYLAXIS; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVALUATION; FEMALE; HEADACHE; HEART PALPITATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOT FLUSH; HUMAN; HYPOTENSION; INCIDENCE; IRON DEFICIENCY ANEMIA; LONG TERM CARE; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SINGLE DRUG DOSE; TACHYCARDIA; TASTE DISORDER; VASODILATATION; VOMITING;

AGED; ANEMIA, IRON-DEFICIENCY; DRUG HYPERSENSITIVITY; FEMALE; FERRIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 2942709724     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh222     Document Type: Article

References (17)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
2. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: 433-439
3. Markowitz GS, Kahn A, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 28: 34-40
4. Fudin R, Jaichenko J, Shostak A et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79: 299-305
5. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731
6. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-1839
7. Rolla G, Bucca C, Brussino L. Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor. J Allergy Clin Immunol 1994; 93: 1074-1075
8. Folkert VW, Michael B, Agarwal R et al. Chronic use of sodium ferric gluconate complex (SFGC) in hemodialysis patients: safety of higher dose (≥250 mg) administration. Am J Kidney Dis 2003; 41: 651-657
9. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients: II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-224
10. US Renal Data System. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2001
11. Fishbane S, Ungureanu VD, Maesaka JK et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-534
12. van Wyck DB, Bailie G, Aronoff G. Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis 2002; 39: 426-432
13. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33: 464-470
14. Auerbach M, Witt D, Toler W et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570
15. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37: 743-749
16. Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 1991; 40: 1148-1152
17. Pegues DA, Beck-Sague CM, Woollen SW et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992; 42: 1232-1237